{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:48:31Z","timestamp":1790052511071,"version":"4.0.1"},"reference-count":62,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Evidence on the association between systemic glucocorticoid use and colorectal cancer (CRC) risk is limited. This study aimed to determine whether systemic glucocorticoid use is associated with an increased risk of overall CRC (diagnosed at any age) and early-onset CRC (EOCRC; diagnosed before 50 years of age).\n                    <jats:bold>Methods:<\/jats:bold>\n                    A nationwide cohort study (follow-up: 2005\u20132018) was conducted using data from multiple nationwide registers in Sweden. The study included 10,921,991 individuals, of whom 2,174,744 used glucocorticoids; among these, 54,443 were newly diagnosed with CRC. The risk of CRC among glucocorticoid users versus nonusers was compared using standardized incidence ratios (SIRs), stratified by medication type and dose.\n                    <jats:bold>Results:<\/jats:bold>\n                    Compared with individuals who did not use systemic glucocorticoids, a significantly increased risk of CRC was observed among users of dexamethasone (overall SIR, 2.9; 95% CI, 2.0\u20134.2; EOCRC SIR, 27; 95% CI, 5.5\u201379), betamethasone (overall SIR, 1.5; 95% CI, 1.4\u20131.5; EOCRC SIR, 2.3; 95% CI, 2.0\u20132.7), prednisolone (overall SIR, 1.2; 95% CI, 1.2\u20131.3; EOCRC SIR, 1.8; 95% CI, 1.4\u20132.3), and other systemic glucocorticoids (SIR, 1.4; 95% CI, 1.3\u20131.5; EOCRC SIR, 2.2; 95% CI, 1.5\u20133.2). Similar patterns were observed among individuals with a family history of CRC. A high cumulative dose of betamethasone was associated with further increased CRC risk (high-dose tertile SIR, 1.7; 95% CI, 1.6\u20131.7; medium-dose SIR, 1.3; 95% CI, 1.2\u20131.4; low-dose SIR, 1.4; 95% CI, 1.3\u20131.5).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Our large-scale cohort study showed that systemic glucocorticoid use is associated with an increased risk of CRC, particularly EOCRC. This study also identifies new high-risk groups who are candidates for earlier, risk-adapted CRC screening or preventive interventions.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7113","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:37Z","timestamp":1773318697000},"source":"Crossref","is-referenced-by-count":1,"title":["Systemic Glucocorticoid Use and Risk of Colorectal Cancer, Especially Early-Onset Type: A Nationwide Cohort Study"],"prefix":"10.6004","volume":"24","author":[{"given":"Zehui","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Primary Cancer Prevention, Risk Adapted Cancer Prevention Group, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Kharazmi","sequence":"additional","affiliation":[{"name":"Division of Primary Cancer Prevention, Risk Adapted Cancer Prevention Group, German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Clinical Sciences, Center for Primary Health Care Research, Lund University, Malmo, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Primary Cancer Prevention, Risk Adapted Cancer Prevention Group, German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sundquist","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Center for Primary Health Care Research, Lund University, Malmo, Sweden"},{"name":"University Clinic Primary Care Skane, Region Skane, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sundquist","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Center for Primary Health Care Research, Lund University, Malmo, Sweden"},{"name":"University Clinic Primary Care Skane, Region Skane, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Fallah","sequence":"additional","affiliation":[{"name":"Division of Primary Cancer Prevention, Risk Adapted Cancer Prevention Group, German Cancer Research Center (DKFZ), Heidelberg, Germany"},{"name":"Department of Clinical Sciences, Center for Primary Health Care Research, Lund University, Malmo, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL,  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209\u2013249."},{"key":"B2","series-title":"Transl Oncol","first-page":"101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi Y","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021;14:101174."},{"key":"B3","series-title":"Int J Mol Sci","first-page":"5421","article-title":"Inflammation-induced tumorigenesis and metastasis","volume":"22","author":"Hibino S","year":"2021","unstructured":"Hibino S, Kawazoe T, Kasahara H,  Inflammation-induced tumorigenesis and metastasis. Int J Mol Sci 2021;22:5421."},{"key":"B4","series-title":"Front Endocrinol (Lausanne)","first-page":"1161768","article-title":"Glucocorticoid regulation of cancer development and progression","volume":"14","author":"Khadka S","year":"2023","unstructured":"Khadka S, Druffner SR, Duncan BC, Busada JT. Glucocorticoid regulation of cancer development and progression. Front Endocrinol (Lausanne) 2023;14:1161768."},{"key":"B5","series-title":"Nat Rev Immunol","first-page":"233","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain DW","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017;17:233\u2013247."},{"key":"B6","series-title":"Semin Immunopathol","first-page":"669","article-title":"Control of immunity by glucocorticoids in health and disease","volume":"42","author":"Shimba A","year":"2020","unstructured":"Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol 2020;42:669\u2013680."},{"key":"B7","series-title":"Cancer Prev Res (Phila)","first-page":"1017","article-title":"Long-term glucocorticoid use and cancer risk: a population-based cohort study in South Korea","volume":"13","author":"Oh TK","year":"2020","unstructured":"Oh TK, Song IA. Long-term glucocorticoid use and cancer risk: a population-based cohort study in South Korea. Cancer Prev Res (Phila) 2020;13:1017\u20131026."},{"key":"B8","series-title":"Nat Rev Endocrinol","first-page":"540","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li JX","year":"2022","unstructured":"Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 2022;18:540\u2013557."},{"key":"B9","series-title":"Am J Gastroenterol","first-page":"1103","article-title":"Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: a nationwide cohort study","volume":"115","author":"Khan UA","year":"2020","unstructured":"Khan UA, Fallah M, Tian Y,  Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: a nationwide cohort study. Am J Gastroenterol 2020;115:1103\u20131109."},{"key":"B10","series-title":"Aliment Pharmacol Ther","first-page":"1026","article-title":"Letter: glucocorticoids use and the risk of colorectal cancer","volume":"37","author":"Lai SW","year":"2013","unstructured":"Lai SW, Liao KF, Li CI. Letter: glucocorticoids use and the risk of colorectal cancer. Aliment Pharmacol Ther 2013;37:1026\u20131027."},{"key":"B11","series-title":"Diabet Med","first-page":"1011","article-title":"Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group","volume":"35","author":"Roberts A","year":"2018","unstructured":"Roberts A, James J, Dhatariya K. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 2018;35:1011\u20131017."},{"key":"B12","series-title":"Aliment Pharmacol Ther","first-page":"146","article-title":"Use of systemic glucocorticoids and the risk of colorectal cancer","volume":"37","author":"Ostenfeld EB","year":"2013","unstructured":"Ostenfeld EB, Erichsen R, Thorlacius-Ussing O,  Use of systemic glucocorticoids and the risk of colorectal cancer. Aliment Pharmacol Ther 2013;37:146\u2013152."},{"key":"B13","series-title":"BMJ","first-page":"l803","article-title":"Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study","volume":"364","author":"Tian Y","year":"2019","unstructured":"Tian Y, Kharazmi E, Sundquist K,  Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study. BMJ 2019;364:l803."},{"key":"B14","series-title":"Cancer","first-page":"2837","article-title":"Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history","volume":"126","author":"Mukama T","year":"2020","unstructured":"Mukama T, Kharazmi E, Sundquist K,  Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history. Cancer 2020;126:2837\u20132848."},{"key":"B15","series-title":"Popul Health Metr","first-page":"2","article-title":"Methodological choices affect cancer incidence rates: a cohort study","volume":"15","author":"Brooke HL","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, Feychting M, Ljung R. Methodological choices affect cancer incidence rates: a cohort study. Popul Health Metr 2017;15:2."},{"key":"B16","series-title":"J Oncol Pharm Pract","first-page":"1482","article-title":"Routine antiemetic prophylaxis with dexamethasone during COVID-19: should oncologists reconsider?","volume":"26","author":"Marinella MA","year":"2020","unstructured":"Marinella MA. Routine antiemetic prophylaxis with dexamethasone during COVID-19: should oncologists reconsider? J Oncol Pharm Pract 2020;26:1482\u20131485."},{"key":"B17","series-title":"Oncol Rep","first-page":"427","article-title":"Dexamethasone induces aberrant macrophage immune function and apoptosis","volume":"43","author":"Ai F","year":"2020","unstructured":"Ai F, Zhao G, Lv W,  Dexamethasone induces aberrant macrophage immune function and apoptosis. Oncol Rep 2020;43:427\u2013436."},{"key":"B18","series-title":"Cancer Treat Rev","first-page":"102821","article-title":"Early-onset colorectal cancer: from the laboratory to the clinic","volume":"130","author":"Gandini A","year":"2024","unstructured":"Gandini A, Taieb J, Blons H,  Early-onset colorectal cancer: from the laboratory to the clinic. Cancer Treat Rev 2024;130:102821."},{"key":"B19","series-title":"Dig Dis","first-page":"710","article-title":"Diet and lifestyle habits in early-onset colorectal cancer: a pilot case-control study","volume":"40","author":"Puzzono M","year":"2022","unstructured":"Puzzono M, Mannucci A, Di Leo M,  Diet and lifestyle habits in early-onset colorectal cancer: a pilot case-control study. Dig Dis 2022;40:710\u2013718."},{"key":"B20","series-title":"Dig Dis Sci","first-page":"419","article-title":"Historical obesity and early-onset cancers: a propensity-weighted analysis of the National Health and Nutrition Examination Survey","volume":"69","author":"Hussan H","year":"2024","unstructured":"Hussan H, Patel A, Ma J,  Historical obesity and early-onset cancers: a propensity-weighted analysis of the National Health and Nutrition Examination Survey. Dig Dis Sci 2024;69:419\u2013425."},{"key":"B21","series-title":"J Clin Oncol","first-page":"81","article-title":"Alteration of metabolic syndrome and the risk of colorectal cancer in individuals younger than 50 years","volume":"42","author":"Jin EH","year":"2024","unstructured":"Jin EH. Alteration of metabolic syndrome and the risk of colorectal cancer in individuals younger than 50 years. J Clin Oncol 2024;42(Suppl):Abstract 81."},{"key":"B22","series-title":"Steroids","first-page":"109239","article-title":"Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth","volume":"195","author":"Wang R","year":"2023","unstructured":"Wang R, Guo Q, Ma M, Shi X. Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth. Steroids 2023;195:109239."},{"key":"B23","series-title":"Eur J Clin Pharmacol","first-page":"47","article-title":"Change in glucose metabolism after long-term treatment with deflazacort and betamethasone","volume":"43","author":"Bruno A","year":"1992","unstructured":"Bruno A, Pagano G, Benzi L,  Change in glucose metabolism after long-term treatment with deflazacort and betamethasone. Eur J Clin Pharmacol 1992;43:47\u201350."},{"key":"B24","series-title":"Front Oncol","first-page":"1005","article-title":"Mendelian randomization study: the association between metabolic pathways and colorectal cancer risk","volume":"10","author":"Jung SY","year":"2020","unstructured":"Jung SY, Papp JC, Sobel EM, Zhang ZF. Mendelian randomization study: the association between metabolic pathways and colorectal cancer risk. Front Oncol 2020;10:1005."},{"key":"B25","series-title":"Int J Mol Sci","first-page":"12409","article-title":"Diabetes and colorectal cancer risk: a new look at molecular mechanisms and potential role of novel antidiabetic agents","volume":"22","author":"Vekic J","year":"2021","unstructured":"Vekic J, Zeljkovic A, Stefanovic A,  Diabetes and colorectal cancer risk: a new look at molecular mechanisms and potential role of novel antidiabetic agents. Int J Mol Sci 2021;22:12409."},{"key":"B26","series-title":"Nat Rev Endocrinol","first-page":"540","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li JX","year":"2022","unstructured":"Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 2022;18:540\u2013557."},{"key":"B27","series-title":"Physiol Behav","first-page":"112587","article-title":"Sex differences in glucocorticoids-induced anabolic effects in rats","volume":"209","author":"Stopa LRS","year":"2019","unstructured":"Stopa LRS, de Souza CF, Santos GF,  Sex differences in glucocorticoids-induced anabolic effects in rats. Physiol Behav 2019;209:112587."},{"key":"B28","series-title":"Diabetes Metab","first-page":"321","article-title":"Dexamethasone-induced insulin resistance shows no gender difference in healthy humans","volume":"30","author":"Binnert C","year":"2004","unstructured":"Binnert C, Ruchat S, Nicod N, Tappy L. Dexamethasone-induced insulin resistance shows no gender difference in healthy humans. Diabetes Metab 2004;30:321\u2013326."},{"key":"B29","series-title":"Expert Opin Drug Saf","first-page":"457","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray M","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N,  Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016;15:457\u2013465."},{"key":"B30","series-title":"Int J Biol Sci","first-page":"1530","article-title":"Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers","volume":"17","author":"Yang R","year":"2021","unstructured":"Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci 2021;17:1530\u20131537."},{"key":"B31","series-title":"Breast Cancer Res","first-page":"142","article-title":"No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study","volume":"20","author":"Frisk G","year":"2018","unstructured":"Frisk G, Ekberg S, Lidbrink E,  No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. Breast Cancer Res 2018;20:142."},{"key":"B1","series-title":"CA Cancer J Clin","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL,  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209\u2013249."},{"key":"B2","series-title":"Transl Oncol","first-page":"101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi Y","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol 2021;14:101174."},{"key":"B3","series-title":"Int J Mol Sci","first-page":"5421","article-title":"Inflammation-induced tumorigenesis and metastasis","volume":"22","author":"Hibino S","year":"2021","unstructured":"Hibino S, Kawazoe T, Kasahara H,  Inflammation-induced tumorigenesis and metastasis. Int J Mol Sci 2021;22:5421."},{"key":"B4","series-title":"Front Endocrinol (Lausanne)","first-page":"1161768","article-title":"Glucocorticoid regulation of cancer development and progression","volume":"14","author":"Khadka S","year":"2023","unstructured":"Khadka S, Druffner SR, Duncan BC, Busada JT. Glucocorticoid regulation of cancer development and progression. Front Endocrinol (Lausanne) 2023;14:1161768."},{"key":"B5","series-title":"Nat Rev Immunol","first-page":"233","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain DW","year":"2017","unstructured":"Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017;17:233\u2013247."},{"key":"B6","series-title":"Semin Immunopathol","first-page":"669","article-title":"Control of immunity by glucocorticoids in health and disease","volume":"42","author":"Shimba A","year":"2020","unstructured":"Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol 2020;42:669\u2013680."},{"key":"B7","series-title":"Cancer Prev Res (Phila)","first-page":"1017","article-title":"Long-term glucocorticoid use and cancer risk: a population-based cohort study in South Korea","volume":"13","author":"Oh TK","year":"2020","unstructured":"Oh TK, Song IA. Long-term glucocorticoid use and cancer risk: a population-based cohort study in South Korea. Cancer Prev Res (Phila) 2020;13:1017\u20131026."},{"key":"B8","series-title":"Nat Rev Endocrinol","first-page":"540","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li JX","year":"2022","unstructured":"Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 2022;18:540\u2013557."},{"key":"B9","series-title":"Am J Gastroenterol","first-page":"1103","article-title":"Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: a nationwide cohort study","volume":"115","author":"Khan UA","year":"2020","unstructured":"Khan UA, Fallah M, Tian Y,  Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: a nationwide cohort study. Am J Gastroenterol 2020;115:1103\u20131109."},{"key":"B10","series-title":"Aliment Pharmacol Ther","first-page":"1026","article-title":"Letter: glucocorticoids use and the risk of colorectal cancer","volume":"37","author":"Lai SW","year":"2013","unstructured":"Lai SW, Liao KF, Li CI. Letter: glucocorticoids use and the risk of colorectal cancer. Aliment Pharmacol Ther 2013;37:1026\u20131027."},{"key":"B11","series-title":"Diabet Med","first-page":"1011","article-title":"Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group","volume":"35","author":"Roberts A","year":"2018","unstructured":"Roberts A, James J, Dhatariya K. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 2018;35:1011\u20131017."},{"key":"B12","series-title":"Aliment Pharmacol Ther","first-page":"146","article-title":"Use of systemic glucocorticoids and the risk of colorectal cancer","volume":"37","author":"Ostenfeld EB","year":"2013","unstructured":"Ostenfeld EB, Erichsen R, Thorlacius-Ussing O,  Use of systemic glucocorticoids and the risk of colorectal cancer. Aliment Pharmacol Ther 2013;37:146\u2013152."},{"key":"B13","series-title":"BMJ","first-page":"l803","article-title":"Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study","volume":"364","author":"Tian Y","year":"2019","unstructured":"Tian Y, Kharazmi E, Sundquist K,  Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study. BMJ 2019;364:l803."},{"key":"B14","series-title":"Cancer","first-page":"2837","article-title":"Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history","volume":"126","author":"Mukama T","year":"2020","unstructured":"Mukama T, Kharazmi E, Sundquist K,  Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history. Cancer 2020;126:2837\u20132848."},{"key":"B15","series-title":"Popul Health Metr","first-page":"2","article-title":"Methodological choices affect cancer incidence rates: a cohort study","volume":"15","author":"Brooke HL","year":"2017","unstructured":"Brooke HL, Talb\u00e4ck M, Feychting M, Ljung R. Methodological choices affect cancer incidence rates: a cohort study. Popul Health Metr 2017;15:2."},{"key":"B16","series-title":"J Oncol Pharm Pract","first-page":"1482","article-title":"Routine antiemetic prophylaxis with dexamethasone during COVID-19: should oncologists reconsider?","volume":"26","author":"Marinella MA","year":"2020","unstructured":"Marinella MA. Routine antiemetic prophylaxis with dexamethasone during COVID-19: should oncologists reconsider? J Oncol Pharm Pract 2020;26:1482\u20131485."},{"key":"B17","series-title":"Oncol Rep","first-page":"427","article-title":"Dexamethasone induces aberrant macrophage immune function and apoptosis","volume":"43","author":"Ai F","year":"2020","unstructured":"Ai F, Zhao G, Lv W,  Dexamethasone induces aberrant macrophage immune function and apoptosis. Oncol Rep 2020;43:427\u2013436."},{"key":"B18","series-title":"Cancer Treat Rev","first-page":"102821","article-title":"Early-onset colorectal cancer: from the laboratory to the clinic","volume":"130","author":"Gandini A","year":"2024","unstructured":"Gandini A, Taieb J, Blons H,  Early-onset colorectal cancer: from the laboratory to the clinic. Cancer Treat Rev 2024;130:102821."},{"key":"B19","series-title":"Dig Dis","first-page":"710","article-title":"Diet and lifestyle habits in early-onset colorectal cancer: a pilot case-control study","volume":"40","author":"Puzzono M","year":"2022","unstructured":"Puzzono M, Mannucci A, Di Leo M,  Diet and lifestyle habits in early-onset colorectal cancer: a pilot case-control study. Dig Dis 2022;40:710\u2013718."},{"key":"B20","series-title":"Dig Dis Sci","first-page":"419","article-title":"Historical obesity and early-onset cancers: a propensity-weighted analysis of the National Health and Nutrition Examination Survey","volume":"69","author":"Hussan H","year":"2024","unstructured":"Hussan H, Patel A, Ma J,  Historical obesity and early-onset cancers: a propensity-weighted analysis of the National Health and Nutrition Examination Survey. Dig Dis Sci 2024;69:419\u2013425."},{"key":"B21","series-title":"J Clin Oncol","first-page":"81","article-title":"Alteration of metabolic syndrome and the risk of colorectal cancer in individuals younger than 50 years","volume":"42","author":"Jin EH","year":"2024","unstructured":"Jin EH. Alteration of metabolic syndrome and the risk of colorectal cancer in individuals younger than 50 years. J Clin Oncol 2024;42(Suppl):Abstract 81."},{"key":"B22","series-title":"Steroids","first-page":"109239","article-title":"Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth","volume":"195","author":"Wang R","year":"2023","unstructured":"Wang R, Guo Q, Ma M, Shi X. Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth. Steroids 2023;195:109239."},{"key":"B23","series-title":"Eur J Clin Pharmacol","first-page":"47","article-title":"Change in glucose metabolism after long-term treatment with deflazacort and betamethasone","volume":"43","author":"Bruno A","year":"1992","unstructured":"Bruno A, Pagano G, Benzi L,  Change in glucose metabolism after long-term treatment with deflazacort and betamethasone. Eur J Clin Pharmacol 1992;43:47\u201350."},{"key":"B24","series-title":"Front Oncol","first-page":"1005","article-title":"Mendelian randomization study: the association between metabolic pathways and colorectal cancer risk","volume":"10","author":"Jung SY","year":"2020","unstructured":"Jung SY, Papp JC, Sobel EM, Zhang ZF. Mendelian randomization study: the association between metabolic pathways and colorectal cancer risk. Front Oncol 2020;10:1005."},{"key":"B25","series-title":"Int J Mol Sci","first-page":"12409","article-title":"Diabetes and colorectal cancer risk: a new look at molecular mechanisms and potential role of novel antidiabetic agents","volume":"22","author":"Vekic J","year":"2021","unstructured":"Vekic J, Zeljkovic A, Stefanovic A,  Diabetes and colorectal cancer risk: a new look at molecular mechanisms and potential role of novel antidiabetic agents. Int J Mol Sci 2021;22:12409."},{"key":"B26","series-title":"Nat Rev Endocrinol","first-page":"540","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li JX","year":"2022","unstructured":"Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol 2022;18:540\u2013557."},{"key":"B27","series-title":"Physiol Behav","first-page":"112587","article-title":"Sex differences in glucocorticoids-induced anabolic effects in rats","volume":"209","author":"Stopa LRS","year":"2019","unstructured":"Stopa LRS, de Souza CF, Santos GF,  Sex differences in glucocorticoids-induced anabolic effects in rats. Physiol Behav 2019;209:112587."},{"key":"B28","series-title":"Diabetes Metab","first-page":"321","article-title":"Dexamethasone-induced insulin resistance shows no gender difference in healthy humans","volume":"30","author":"Binnert C","year":"2004","unstructured":"Binnert C, Ruchat S, Nicod N, Tappy L. Dexamethasone-induced insulin resistance shows no gender difference in healthy humans. Diabetes Metab 2004;30:321\u2013326."},{"key":"B29","series-title":"Expert Opin Drug Saf","first-page":"457","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray M","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N,  Long-term side effects of glucocorticoids. Expert Opin Drug Saf 2016;15:457\u2013465."},{"key":"B30","series-title":"Int J Biol Sci","first-page":"1530","article-title":"Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers","volume":"17","author":"Yang R","year":"2021","unstructured":"Yang R, Yu Y. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers. Int J Biol Sci 2021;17:1530\u20131537."},{"key":"B31","series-title":"Breast Cancer Res","first-page":"142","article-title":"No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study","volume":"20","author":"Frisk G","year":"2018","unstructured":"Frisk G, Ekberg S, Lidbrink E,  No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. Breast Cancer Res 2018;20:142."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e257113.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e257113.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e257113.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:37Z","timestamp":1773318697000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e257113.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":62,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7113","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}